APAC 2025 CBD/THC Risk Map: Thailand’s U‑Turn, Japan’s Residue Limits, Hong Kong’s Ban, and Singapore’s Zero‑Tolerance

APAC CBD/THC regulations 2025: why the risk picture changed fast

Across the Asia‑Pacific region, 2025 was not a “steady growth” year for CBD—it was a compliance reset.

Four jurisdictions in particular became high‑impact for cross‑border commerce:

• Thailand pivoted toward a medical‑only posture and tightened retail rules around flower/bud sales.
• Japan moved to an ingredient/content-based regime with explicit THC residue limits by product form.
• Hong Kong maintained and actively enforced a total CBD ban by classifying CBD as a dangerous drug.
• Singapore continued zero tolerance for plant‑derived cannabinoids and warned that even trace‑amount products are risky.

For brands, marketplaces, and 3PL operators, these changes were not abstract: they directly affected e‑commerce routing, influencer campaigns, warehouse placement, payment approvals, and the likelihood of customs seizure.

This APAC risk map is informational only, not legal advice. Always confirm local requirements with counsel and your logistics providers before shipping.

What tightened in 2025 (and why it matters to operators)

The region shifted from “source-based” to “residue-based” enforcement

Historically, some APAC markets focused on what part of the plant an extract came from or whether a product was positioned as a medicine vs food/cosmetic. By 2025, the practical enforcement trend increasingly centered on measurable residue (especially for THC), document traceability, and strict border control.

Japan is the clearest example: product legality hinges on measurable THC residue thresholds, not marketing language. Meanwhile, Hong Kong and Singapore demonstrate the other side of the spectrum: no meaningful tolerance for CBD products in consumer channels.

Cross-border e-commerce and “in transit” risk grew

Even if a destination allows a CBD product, transit through a zero‑tolerance hub can be a problem when customs screening flags a shipment.

Hong Kong Customs has explicitly stated it will intercept import and transit movements of CBD products across channels, with severe penalties under the Dangerous Drugs Ordinance framework. See the official notice: https://www.info.gov.hk/gia/general/202301/27/P2023012700369.htm

Country-by-country matrix (ingredient legality, THC residue, labeling proofs, carrier realities)

The matrix below is written as a scannable, country-by-country compliance checklist (no tables), designed for compliance officers building APAC catalog rules.

Thailand (high volatility, “medical-only” direction)

Ingredient legality

Thailand’s policy environment has been volatile since decriminalization, and 2025 introduced a clearer move to restricting consumer access. A key 2025 development was the Ministry of Public Health announcement treating certain flowering parts as a controlled herb and tightening sales channels.

• Businesses should assume flower/bud retail is highly scrutinized and shifting toward clinical/medical framing.
• Extracts and finished goods are still subject to Thai FDA-style product pathways, and import by individuals can be a problem.

Allowed THC residue

Thailand is not the centerpiece of the APAC “residue limit” story (Japan is). Still, operators should expect THC content and classification to be central to Thai enforcement and licensing.

Labeling proofs and documentation

Expect requests for:

• Chain-of-custody documentation from licensed sources
• Batch COAs from ISO/IEC 17025-aligned labs (best practice)
• Local authorization where applicable (Thai registrations/permissions)

In 2025, industry legal analyses and reporting highlighted new obligations tied to sourcing and controlled-herb compliance (including recordkeeping and supply documentation) as rules tightened.

Advertising / marketing constraints

Thailand’s 2025 tightening included restrictions on the retail sale of flower/buds and public-facing marketing. Third-party promotions (including influencer content) became riskier because platform evidence can be used in enforcement.

Operational risk rating

Medium to high (not because everything is banned, but because rules are evolving and enforcement posture can shift quickly).

Key sources

• Reuters reporting on medical certificate requirements and tightening intentions: https://www.reuters.com/business/healthcare-pharmaceuticals/thailand-require-medical-certificates-buying-cannabis-2025-05-22/
• Reporting on the 2025 tightening effective late June 2025: https://www.aljazeera.com/news/2025/6/26/thailand-moves-to-re-criminalise-cannabis-in-blow-to-1bn-industry

Japan (strict but workable with formulation discipline)

Japan is the most important “rules-by-the-numbers” jurisdiction in this risk map.

Ingredient legality

Japan’s reforms moved the industry toward a framework where legality hinges on THC residue limits, supported by standardized testing expectations. The broader legal changes took effect on December 12, 2024 (a key timeline anchor for 2025 operations).

• Kyodo and other reporting covered the revised laws taking effect Dec 12, 2024: https://english.kyodonews.net/news/2024/09/b95f4cbb4efd-japans-revised-laws-criminalizing-cannabis-use-take-effect-dec-12.html

Allowed THC residue (form-based thresholds)

Japan adopted different maximum THC residue limits depending on product form. Compliance teams should build SKUs around these categories:

• Oils / fats / oil-like products: 10 mg/kg (10 ppm)
• Beverages / aqueous solutions: 0.10 mg/kg (0.1 ppm)
• Other product categories (commonly interpreted as many foods/edibles and other forms): 1 mg/kg (1 ppm)

These values were widely reported as part of Japan’s regulatory updates and have been discussed as among the strictest globally.

Testing methods and lab expectations

Japan’s Ministry of Health, Labour and Welfare (MHLW) circulated a draft standard analytical method for measuring THC in plant-derived products, using approaches such as LC‑MS/MS, aligning enforcement with measurable thresholds.

Industry coverage referencing the draft method and the levels it is designed to detect: https://cosmetic.chemlinked.com/news/cosmetic-news/japan-enhances-supervision-of-cannabis-related-controlled-products

Labeling proofs and “ready-to-ship” document pack

Japan’s market reality is that documentation is part of the product. For imports, B2B sales, and marketplace onboarding, maintain a pack that includes:

• Batch-specific COA showing THC result and LOQ/LOD (limit of quantification/detection)
• Method statement (analytical method used; instrument type; whether THC + THCA are considered)
• Ingredient traceability statement (supplier, lot, and manufacturing site)
• Product form classification (oil vs beverage vs other) to map to the right threshold
• Japanese-language label set (where applicable) consistent with product category rules

Operational risk rating

Medium (strict, but navigable when products are engineered to pass residue limits).

Key sources

• Discussion of the proposed/updated residue levels: https://businessofcannabis.com/japan-issues-update-on-new-thc-limits-in-cbd-products-which-remain-strictest-in-the-world/
• Additional industry reporting describing the levels: https://mjbizdaily.com/news/proposed-thc-regulations-threaten-japanese-cbd-industry/391991/

Hong Kong (total CBD prohibition and active customs enforcement)

Ingredient legality

Hong Kong classifies CBD as a dangerous drug under the Dangerous Drugs Ordinance framework. The ban took effect February 1, 2023, and it remains a major APAC enforcement trap in 2025 for e-commerce and travelers.

Official government statement that the control came into effect Feb 1: https://www.info.gov.hk/gia/general/202301/31/P2023013100299.htm

Allowed THC residue

From a practical compliance standpoint: not applicable for consumer CBD products because CBD itself is controlled.

Labeling proofs

COAs generally do not solve the problem in Hong Kong because the issue is not “how much THC,” it is the presence of CBD.

Customs and enforcement posture

Hong Kong Customs publicly committed to vigorous enforcement and specifically highlighted intercepting import and transit movements of CBD products.

• Customs enforcement notice: https://www.info.gov.hk/gia/general/202301/27/P2023012700369.htm
• Narcotics Division portal (policy and public messaging): https://www.nd.gov.hk/en/CBD.html

Penalties can be severe for trafficking/manufacturing, and possession also carries significant risk.

Operational risk rating

Very high (avoid shipping, avoid transshipment routing, avoid storing inventory).

Singapore (zero-tolerance and extraterritorial enforcement risks)

Ingredient legality

Singapore’s Central Narcotics Bureau (CNB) is explicit that hemp and CBD oil products derived from the plant are treated as Class A controlled substances. Importing, selling, possessing, or consuming them—even “trace amounts”—is prohibited.

CNB FAQ: https://www.cnb.gov.sg/singapore-drug-situation/myths-and-facts-about-drugs/cannabis/faqs-about-hemp-and-cbd-oil-products/

Allowed THC residue

For compliance planning: treat as zero-tolerance in consumer channels.

Labeling proofs

As with Hong Kong, a COA does not eliminate risk when the policy position is strict prohibition. Singapore authorities have repeatedly warned that labels may be unreliable and that products can contain controlled drugs despite claims.

Extraterritorial exposure

Singapore also emphasizes that consumption overseas can still create enforcement consequences for Singapore citizens and PRs, reinforcing the broader deterrence posture.

• CNB advisory page (overseas consumption enforcement messaging): https://www.cnb.gov.sg/mediaroom/news/advisory-on-the-abuse-possession-sale-and-importation-of-cannabis-and-cannabis-products/

Operational risk rating

Very high (avoid shipping, avoid transshipment routing, avoid influencer targeting).

High-risk transit hubs and routing strategy (APAC logistics reality)

Why transit matters as much as destination

In APAC, shipments commonly route through large hubs for cost and speed. But in 2025, CBD/THC products experienced a growing risk that:

• the package is flagged by automated screening,
• customs inspects it during transshipment,
• the shipment is delayed, returned, or seized,
• the brand must manage refunds/chargebacks and potential regulator contact.

Hubs and lanes to treat as high-risk for CBD shipments

Based on enforcement posture described above, build your routing rules to avoid:

• Hong Kong as a transit point for any CBD-containing SKU
• Singapore as a transit point for any CBD-containing SKU

If you must route within APAC, consider configuring lanes that:

• ship direct into Japan (where possible) rather than cross-docking in a zero-tolerance jurisdiction,
• keep SKU-level restrictions in your WMS/TMS so restricted SKUs cannot be allocated to a risky lane.

Marketplace and payment restrictions: the “silent blockers” of APAC expansion

Payment processors often apply stricter rules than regulators

Even when a product is legal in a destination, payment providers may classify CBD as restricted or unacceptable risk depending on jurisdiction, merchant category, and perceived chargeback/fraud risk.

• Stripe maintains “restricted/prohibited business” frameworks (review your local Stripe entity policy and get written approval before processing).
• PayPal’s various acceptable-use terms often restrict CBD/hemp product categories unless explicitly approved.

The operational lesson: do not treat payment approval as a back-office afterthought. Build your APAC go-to-market plan around what your processor will actually underwrite.

Marketplace policies can be stricter than law

In Japan, marketplace listings may be removed or rejected unless sellers can provide:

• COAs
• ingredient traceability
• proof that the product fits the relevant category rules

Even when the law allows a product at a given residue threshold, marketplaces can adopt a more conservative standard to reduce risk.

Japan playbook: SKU reformulation to hit residue thresholds

Japan is where compliance teams can win with engineering discipline. The goal is to align product form with the strictest applicable threshold.

Step 1: classify your SKU by Japan’s form-based threshold logic

Treat every SKU as one of:

• Oil/fat/powder-like
• Beverage/aqueous solution
• Other

Your classification drives your allowable THC residue limit, so it must be documented internally and defensible.

Step 2: set internal action limits below the legal maximum

Do not formulate to the legal ceiling. Set an internal “action limit” to account for:

• lab measurement uncertainty,
• lot-to-lot variability,
• degradation over shelf life,
• cross-contamination risk.

A common compliance approach is to target a fraction of the regulatory maximum (for example, half or less), especially for beverages where the limit is extremely low.

Step 3: redesign extraction and purification around the tightest category

For Japan-bound SKUs:

• Prefer inputs and processes that minimize THC carryover.
• Tighten cleaning validation and changeover procedures if you manufacture multiple cannabinoid products.
• Audit upstream suppliers for process controls and credible lab testing.

Step 4: build a Japan-specific release protocol

Before any Japan shipment:

• Release only with a batch COA that states THC result and LOQ/LOD.
• Keep retain samples for dispute resolution.
• Align label claims so they do not create an unintended regulatory category.

Step 5: prepare for customs and “post-import” questions

Have a ready folder (digital + print) containing:

• COAs
• ingredient list
• manufacturing flow description (high level)
• chain-of-custody
• local importer’s contact and responsibilities

Geoblocking, rerouting, and catalog controls (practical compliance engineering)

Geoblocking rules you should implement immediately

For APAC CBD/THC regulations 2025 compliance, implement hard blocks for:

• Hong Kong shipping addresses
• Singapore shipping addresses

And implement soft blocks (manual review) for:

• Thailand orders (depending on SKU type and local pathway)
• Japan orders for any SKU without a Japan-ready document pack

Geoblocking should be applied across:

• storefront checkout,
• marketplace feeds,
• affiliate and influencer coupon links,
• customer service “reship” workflows (common compliance leak).

Rerouting strategy

• Avoid “cheapest route” logic for regulated SKUs.
• Use SKU flags in your TMS/WMS: NO-TRANSIT-SG, NO-TRANSIT-HK.
• Ensure your 3PL contract includes: no re-labeling, no consolidation with unknown goods, and exception handling SLAs.

Carrier policy reality check (what operators actually face)

Even when a jurisdiction permits a product, carriers may restrict it. Carrier rules change frequently and can differ by origin/destination lane.

Practical steps:

• Get written lane approval from your carrier or 3PL.
• Ensure your commercial invoice and HS classification are consistent.
• Avoid marketing language on outer packaging that increases inspection likelihood.

Remember: many carrier policies are built around U.S./EU hemp rules and may not map cleanly to APAC’s stricter thresholds—especially Japan’s beverage limit and Hong Kong/Singapore’s prohibition.

Crisis-response checklist: seized shipments, interdicted orders, refunds, and chargebacks

Interdictions happen. The difference between a contained incident and a brand-damaging spiral is whether you have a playbook.

1) First 24 hours: contain and document

• Open an internal incident ticket with a unique ID.
• Freeze re-shipments for the same SKU and lane.
• Pull all documentation: commercial invoice, airway bill, COA, batch record, packing photos.
• Notify the importer of record (if applicable).

2) Customer communications (do not improvise)

• Use a pre-approved script that avoids speculative legal claims.
• Offer clear options: refund, reship to allowed jurisdiction, or store credit (where permitted).
• Set expectations: customs timelines are unpredictable.

3) Refund and chargeback control

• Refund quickly when interdiction is confirmed to reduce chargebacks.
• Track chargeback reason codes and update fraud rules.
• Temporarily disable payment methods with strict dispute handling if your chargeback ratio spikes.

4) Root-cause analysis (RCA)

• Was it destination illegality (Hong Kong/Singapore)?
• Was it transit routing through a prohibited hub?
• Was it Japan residue threshold failure or missing documentation?
• Was labeling/outer packaging triggering inspection?

5) Corrective actions

• Update geoblocking lists.
• Update lane rules (no HK/SG transit).
• Reformulate or retire non-compliant SKUs for Japan.
• Retrain customer support on reship restrictions.

2025 takeaways for businesses and compliance teams

• Japan is a “precision compliance” market: strict but workable with residue-driven formulation, testing, and documentation.
• Hong Kong is a hard stop: CBD is treated as a dangerous drug; avoid sales, storage, and transit.
• Singapore remains zero-tolerance: avoid sales and transit; document your geoblocking.
• Thailand is volatile: plan for a medical-only direction and tighter retail/advertising constraints.

Next step: build your APAC ruleset in CannabisRegulations.ai

If you’re expanding in APAC, the fastest way to reduce interdictions and marketplace takedowns is to operationalize compliance: SKU flags, residue thresholds, document packs, routing constraints, and customer service scripts.

Use https://cannabisregulations.ai/ to keep your APAC compliance rules current, map product requirements by jurisdiction, and build repeatable workflows for licensing, labeling, testing, and cross-border fulfillment.